| Title: |
The role of [68 Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRA gastrointestinal stromal tumours (GIST). |
| Authors: |
Aloj, Luigi; Giger, Olivier; Mendichovszky, Iosif A; Challis, Ben G; Ronel, Meytar; Harper, Ines; Cheow, Heok; Hoopen, Rogier Ten; Pitfield, Deborah; Gallagher, Ferdia A; Attili, Bala; McLean, Mary; Jones, Robin L; Dileo, Palma; Bulusu, Venkata Ramesh; Maher, Eamonn R; Casey, Ruth T |
| Publisher Information: |
Springer Nature; //doi.org/10.1186/s13550-021-00747-0 |
| Publication Year: |
2021 |
| Collection: |
Apollo - University of Cambridge Repository |
| Subject Terms: |
32 Biomedical and Clinical Sciences; 3202 Clinical Sciences; 3211 Oncology and Carcinogenesis; Cancer; Clinical Research; Neurosciences; Digestive Diseases; Biomedical Imaging; Liver Disease; 4.2 Evaluation of markers and technologies; 4.1 Discovery and preclinical testing of markers and technologies |
| Description: |
BACKGROUND: [68 Ga]Ga-DOTATATE PET/CT is now recognised as the most sensitive functional imaging modality for the diagnosis of well-differentiated neuroendocrine tumours (NET) and can inform treatment with peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE. However, somatostatin receptor (SSTR) expression is not unique to NET, and therefore, [68 Ga]Ga-DOTATATE PET/CT may have oncological application in other tumours. Molecular profiling of gastrointestinal stromal tumours that lack activating somatic mutations in KIT or PDGFRA or so-called 'wild-type' GIST (wtGIST) has demonstrated that wtGIST and NET have overlapping molecular features and has encouraged exploration of shared therapeutic targets, due to a lack of effective therapies currently available for metastatic wtGIST. AIMS: To investigate (i) the diagnostic role of [68 Ga]Ga-DOTATATE PET/CT; and, (ii) to investigate the potential of this imaging modality to guide treatment with [177Lu]Lu-DOTATATE in patients with wtGIST. METHODS: [68 Ga]Ga-DOTATATE PET/CT was performed on 11 patients with confirmed or metastatic wtGIST and one patient with a history of wtGIST and a mediastinal mass suspicious for metastatic wtGIST, who was subsequently diagnosed with a metachronous mediastinal paraganglioma. Tumour expression of somatostatin receptor subtype 2 (SSTR2) using immunohistochemistry was performed on 54 tumour samples including samples from 8/12 (66.6%) patients who took part in the imaging study and 46 tumour samples from individuals not included in the imaging study. RESULTS: [68 Ga]Ga-DOTATATE PET/CT imaging was negative, demonstrating that liver metastases had lower uptake than background liver for nine cases (9/12 cases, 75%) and heterogeneous uptake of somatostatin tracer was noted for two cases (16.6%) of wtGIST. However, [68 Ga]Ga-DOTATATE PET/CT demonstrated intense tracer uptake in a synchronous paraganglioma in one case and a metachronous paraganglioma in another case with wtGIST. CONCLUSIONS: Our data suggest that SSTR2 is not a ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
Electronic; application/pdf |
| Language: |
English |
| Relation: |
https://www.repository.cam.ac.uk/handle/1810/319274 |
| DOI: |
10.17863/CAM.66392 |
| Availability: |
https://www.repository.cam.ac.uk/handle/1810/319274; https://doi.org/10.17863/CAM.66392 |
| Rights: |
Attribution 4.0 International ; https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.D0F959E3 |
| Database: |
BASE |